Monograph Details
|
|
Neoplasms
> Cytoprotective agents
|
|
TOTECT |
| Manufacturer |
|
TopoTarget USA, Inc. |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
Detoxifying agent. |
| Generic Name |
|
Dexrazoxane 500mg; per vial; pwd for IV infusion after reconstitution and dilution; preservative-free. |
| Indications |
|
To treat extravasation resulting from IV anthracycline chemotherapy. |
| Children |
|
Not recommended. |
| Adults |
|
Give once daily for 3 consecutive days by IV infusion over 1–2 hours. Initiate 1st dose as soon as possible and within 1st 6 hours after extravasation. Days 1 and 2: 1000mg/m2; max 2000mg. Day 3: 500mg/m2; max 1000mg. Renal impairment (CrCl <40mL/min): reduce dose by 50%. |
| Precautions |
|
Renal or hepatic impairment (monitor liver enzymes). Monitor for myelosuppression; obtain blood counts periodically. Elderly. Labor & delivery. Pregnancy (Cat.D); avoid use. Nursing mothers: not recommended. |
| Interactions |
|
Avoid dimethylsulfoxide (DMSO). Caution with concurrent cytotoxic chemotherapy (additive cytotoxicity). |
| Adverse Reactions |
|
Inj site reactions, GI upset, stomatitis, leukopenia, neutropenia, thrombocytopenia, elevated liver enzymes, pyrexia, infections. |
| How Supplied |
|
Kit—10 single-use vials (w. diluent) |
| Additional Resources |
|
• Related Prescribing Note |
|
|
|
|
